Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
But hey, that’s the risks one takes if they want that imaginary 10x LESS likely.
Never mind about a-273 trial and what it could mean for the older population, just take herpes medicine along with these possible side effects. Guess what though, it doesn’t guarantee you won’t get Alz, just reduce your chances.
Lol, BP solutions.
What do you think BIIB and their BAN product is? Nothing more than a game of poker against Anavex. Bluffing that they possibly might have something. Another amyloid, that needs to be taken by injection for 12.... wait 18 months to get any shred of improvement. Wait.... that’s using an all new test created by whom?
Yea, and Anavex and their a-273 is suspect.
Wouldn’t allowing non bio marker subjects in any part of the trial be asking for criticism?
I can hear the fud already, never mind how spectacular the results
You know how often misdiagnosis happens in Alz trials?
Seems as if it has to happen pretty often to get the results Anavex is seeing so far.
I’m curious if said participant started driving again. THAT trumps all others as it takes a lot of brain functioning to drive safely.
At least in Hawaii it does.
Nah, more like a-273 would be part of the daily multi vitamin pack
2018 Dementia Grants Program - Round 1 NOW CLOSED
The purpose of this Grant is to fund generously a single, high-quality, innovative and possibly paradigm-changing research project that could transform the landscape of dementia research
That so sounds like words the company used it presentations.
Said it won’t be chosen until Oct 2018.
https://www.dementia.org.au/research/grants
Old news, but since approved for the p2/3 trial, could it be......?
Me thinks a picture could be drawn and some still would act as if they don’t get it.
After all, how could a trial with 25 do more for Alz patients than the last 100-200 trials total.
So with Anavex moving time slots to right before BIIB, is that good or bad?
Curious to know everyone’s thoughts
And on goes the fluff.
I’m sure they have and still are trying to get Avxl on the cheap.
To think otherwise is foolish.
A-273 has done more positive for those 32 trial patients than whatever other ALZ trial BIIB has ran.
FACT
Actually, he was here during that run up in 2015.
Someone seems hurt about it.
Maybe it’s the surprise that a trial or two can start outside of the U.S.?
Lol, the things that are said to see what sticks.
I’m excitedly waiting to see the next angle that’ll try to be used.
Good ol printshop might work.
I remember reading posts at least a year or two ago talking about how big players buy once a trial starts the p3 and never before.
Would that still hold true today?
Nah, Missling is just setting the stage to explain how the trial will run at AAIC.
What the targets will be, and all that other stuff they’ve been working on the past few years.
Markets close @ 1pm anyway, right.
And to think Missling would settle for $20 a share is ludicrous. Anavex and it’s pipeline has the potential to run the tables across CNS diseases.
Sure we have a ways to go yet, and still...... we keep chugging along.
It shows that many simply don’t know about Anavex and the possibilities that it could deliver.
Only time will tell if they will succeed.
Interesting find and discussion today. Why strengthen IP if they have nothing?
Who’s hoodwinking whom?
Nice try to cover up that blunder.
Bottom line, words are words and once the trials start I’m sure another silly excuse will be made as to why Anavex is a bad investment.
For me, I’m waiting for the trials and partial read outs before I decide to either add more, or sell. Until then..... I have 40 years for my 401 AVXL shares to mature.
I already said many times this came up, I don’t buy it. Next
Wait a minute. The data is on the first 3 patients enrolled on a p1/2a study.
Anavex reported on initial 32 for p2a/b and got bashed for it.
Anyone care to explain
Found it. Source is none other than........
Thestreet
Written by......
AF
https://www.google.com/amp/s/www.thestreet.com/amp/story/14082476/1/for-these-small-cap-biotech-ceos-stock-promotion-not-drug-development-was-priority-no-1.html
Don’t take everything you read on here as true.
Just might end up like Cortana and file a lawsuit with that 100 shares
This one?
https://ars.els-cdn.com/content/image/1-s2.0-S2352873718300180-gr1.jpg
I shared it a few weeks back
So just commencing a p3 is a success these days? Come on now.
Ducks are lining up, failures are moving out of the way, and Anavex will have their chance to show what they can do.
Until then, I’m sure there will be many attempts to take my shares.
Nice summary of board topics the last 7 Days.
Although we all shouldn’t get too excited as games are and will still be played.
Retail thinks otherwise.
“To promote the most promising opportunities and address the
corresponding intricacy of these new endeavors, the FDA has introduced
many fundamental advances in how it evaluates drugs for safety and
effectiveness, as well as the manner in which clinical trials are
guided. These include adaptive approaches to clinical development such
as the introduction of seamless trial designs or master protocols or
tissue agnostic product approvals. Each allow us to better marry the
scientific prospect more closely to the approaches that can best
unlock these opportunities.
https://www.news-journal.com/ap/national/statement-from-fda-commissioner-scott-gottlieb-m-d-on-proposed/article_3c3cd278-f6cb-5ad2-b045-9b44a2f32b26.html
I’m from Hawaii. And here you can go from a dormant volcano with snow to a full blown erupting volcano within a span of 3 hours. So we may be the dormant volcano right now, but we can erupt at any time
Ah, the so called “experts” that bleed plaque as the problem. THAT is why there were soooooo many failures.
Hence the waterfall on the website?
Sweeping clinical trials in which thousands of patients are studied for years at a stretch have long been the Holy Grail of medical research—especially when funded by the federal government.
But in the era of personalized medicine, where care can be tailored to a person’s genetic make-up and doctors analyze a patient’s DNA to figure out treatments, big trials are falling out of favor.
Hmm...
https://www.wsj.com/articles/are-big-clinical-trials-relevant-researchers-disagree-1527599699
Attacking website design now? Lol
Yes it’s created on Wordpress just like many small bios.
I even helped them close root access to the site.
I’d much rather have the compound that could possibly work and a plain website than a shinny perty website and no compound ex. AX*N
Yes they are on the right under small molecule disease modifying, tau related and mild-moderate.
Pie chart of ongoing trials for Alz
https://ars.els-cdn.com/content/image/1-s2.0-S2352873718300180-gr1.jpg
With so much failure, and trials going on, one can see why it’s easy to bash ANY of those trials and be over 95% correct.
Bottom line:
I wait for trials to start
I wait for trial results
I re-evaluate from there.
Until then, speculation galore.
May be helping? Lol. Until we get an update of the patients in the Aus trial, we have improved checkpoints SO FAR.
Then again, why wouldn’t they want to take the soc, since it’s proven to slow decline a month or two?
Yup, why slow it a month or two when the side effects aren’t worth it.
4 people I knew died the last 5 years from cancer. Talk about snake oil BP is pushing to the sick.
Yup, it’s why I switched from those chemically made sugars to the regular ol c&h sugar for my coffee.
Sure they can advertise it as a better alternative only to find out years later that it’s linked to the cause of this disease or that problem.
IMO, with the extension into 2020, looks like the data gathered from the p2 will be used to help project what is the expected outcome for the p2/3. Glad they have the compassion to let the trial participants continue their medicine, and hopefully for the better.
One could say that the predators, BP, want to know how Anavex is doing. So they try and force the company to release updates or PRs by any means necessary. The silence is killing them as well because Anavex isn’t “sharing with concerned investors”.
Will they succeed, no one knows. What Anavex IS doing is giving their candidate a shot at goal multiple times. Surviving greed and the likes in the process.